| abstract |
The present invention relates to a pharmaceutical composition for preventing or treating prostatic hyperplasia, comprising mixed extracts of Curcumae Radix and Syzygii Flos as an effective component. The mixed extracts were found to inhibit the expression of dihydrotestosterone, androgen receptors, prostate-specific antigens, proliferating cell nuclear antigen (PCNA), cyclin B1, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB); and to have less adverse side effects compared to an existing prostatic hyperplasia drug, finasteride, and thus may be beneficially used for the prevention or treatment of prostatic hyperplasia. |